Abionic

Abionic is a commercial-stage diagnostics company with a proprietary platform for rapid, near-patient testing. Its core product combines the abioSCOPE® benchtop analyzer with a disposable cartridge to measure the Pancreatic Stone Protein (PSP) biomarker, enabling sepsis detection up to 72 hours earlier than standard clinical recognition. The solution targets hospital emergency departments, ICUs, and wards to accelerate sepsis bundle activation and improve patient outcomes. The company is actively generating clinical evidence to support the adoption of PSP across various patient populations and hospital settings.

The abioSCOPE® is a near-patient rapid diagnostic platform utilizing nanofluidic immunoassay technology. It analyzes a single drop of whole blood (50 µL) in a disposable cartridge to deliver lab-quality quantitative, semi-quantitative, or qualitative results within minutes.

Abionic competes with other point-of-care testing platforms (e.g., Abbott's i-STAT, Roche's cobas, bioMérieux's VIDAS) and established laboratory-based sepsis biomarkers like procalcitonin (PCT) and C-reactive protein (CRP). Its differentiation lies in the combination of its proprietary nanofluidic platform, the specific PSP biomarker claimed to rise earlier, and the very fast time-to-result using whole blood.